Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Approach to Globus Sensation: Clinical Pearls for Clinicians.

Mayo Clinic proceedings·2026
Same author

Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.

The American journal of gastroenterology·2026
Same author

When Does Clostridioides difficile "Recur"? Reconcile Epidemiologic & Bedside Recurrent CDI definitions.

The Journal of infectious diseases·2026
Same author

Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1b Esophageal Adenocarcinoma: A Patient-Level Pooled Analysis of International Studies.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Increasing Incidence and Prevalence of Microscopic Colitis in Sweden: A Nationwide Population-Based Cohort Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

The Epidemiology of Young-Onset Barrett's Esophagus in the United States: A National Population-Based Study Using the TriNetX Database.

Journal of clinical gastroenterology·2026

Related Experiment Video

Updated: Feb 18, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K

Case report: Pentoxifylline treatment in microscopic colitis.

Thomas G Cotter1, Amrit K Kamboj, Stephen Bradley Hicks

  • 1aDepartment of Internal Medicine bDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

Medicine
|November 18, 2017
PubMed
Summary

Pentoxifylline showed limited efficacy for most patients with microscopic colitis, though it was well-tolerated. One patient achieved long-term remission, and a third experienced partial response, suggesting potential in specific cases.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

Related Experiment Videos

Last Updated: Feb 18, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Microscopic colitis is a prevalent cause of chronic diarrhea.
  • Pentoxifylline, an anti-TNF-alpha agent, is used for various conditions.
  • This study assessed pentoxifylline's effectiveness in microscopic colitis patients previously treated with budesonide.

Observation:

  • Nine patients with microscopic colitis (8 collagenous, 1 lymphocytic) were treated with pentoxifylline 400 mg TID for a median of 3 months.
  • Indications for pentoxifylline included budesonide refractoriness (7 patients), dependence (1), or intolerance (1).
  • The median age was 56.9 years, with 89% being female.

Findings:

  • Complete response was observed in 1 patient (11%), who had budesonide intolerance and maintained remission for 43 months.
  • Partial response occurred in 3 patients (33%).
  • No adverse effects were reported during pentoxifylline treatment.

Implications:

  • Pentoxifylline demonstrated limited efficacy in budesonide-experienced microscopic colitis patients.
  • The drug was well-tolerated, with a subset achieving partial or complete response.
  • Further controlled studies are needed to confirm efficacy and identify predictors of response, particularly in non-budesonide-refractory patients.